4CPS-085 Improved access to chemotherapeutic treatment in patients with multiple myeloma

Background and importance A hospital complex has a reference centre that is a tertiary hospital to which is attached a regional hospital located 75 km away. In 2018, in coordination with the pharmacy and haematology service, it was decided to implement a monographic consultation for patient with multiple myeloma in the regional hospital, with the proposal to improve the accessibility of patients to chemotherapeutic treatments and avoid displacement to the centre of reference. Aim and objectives To describe the activity carried out within the scope of a programme to improve accessibility for patients with multiple myeloma. User satisfaction with this new feature was evaluated. Material and methods A retrospective descriptive study was conducted in April 2018 and September 2019. The following variables of the chemotherapy management programme (Farmis-Oncofarm) were recorded: number of patients treated, number of chemotherapy cycles administered and type of chemotherapeutic scheme. To evaluate patient satisfaction, we obtained 30 anonymous and voluntary evaluations in which total satisfaction was rated from 1 to 10 and also satisfaction per item. Results A total of 46 patients were treated during the study period: 58% were men and average age was 62 years. A total of 382 cycles of parenteral chemotherapy and 145 cycles of oral chemotherapy were administered. The schemes used were: VTD (bortezomib–thalidomide–prednisone), VMP (bortezomib–melfalan–prednisone), bortezomib–dexamethasone, daratumumab–bortezomib–dexamethasone, maintenance lenalidomide and Rd (lenalidomide–dexamethasone). Overall satisfaction by patients was 9.4. The best rated items were accessibility to the centre, proximity between the different units (haematology consultation, pharmacy and oncology day hospital) and waiting time. Conclusion and relevance The implemented programme has been highly valued by patients. Seeking strategies aimed at improving the accessibility of patients to hospital treatments should be a priority for the health system. In our case, the pathology required frequent and repeated cycles of chemotherapy in fragile and elderly patients. This added to the ease of administration (subcutaneous and oral routes) making multiple myeloma a candidate pathology to follow-up in a regional hospital without jeopardising patient safety. References and/or acknowledgements No conflict of interest.